Development and Preclinical Evaluation of PET Radiotracers Targeting Adenosine A1 Receptors
- 26 June 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (7) , 1365-1372
Abstract
Several adenosine A1 receptor (A1R) radiotracers for positron emission tomography (PET) have been developed to study their neuromodulatory functions and role in brain disorders. While two xanthine-based radiotracers ([11C]-MPDX and [18F]-CPFPX) have been used in humans, we aimed to improve the metabolic stability and specific binding. Guided by structure-activity relationship (SAR) studies, 10 derivatives were synthesized with binding affinities up to 0.12 nM. Three subnanomolar candidates (3, 8, 9) were radiolabeled with C-11 (t 1/2 = 20.4 min) for evaluation using in vivo PET imaging and ex vivo rodent brain biodistribution. Although [11C]8 demonstrated a higher blood-brain barrier (BBB) permeability, negligible in vivo specific binding was observed. Ex vivo studies indicated that all three compounds are substrates for brain efflux pumps. Despite optimized affinity, BBB permeability and in vivo binding specificity remain challenges. These findings inform development of nonxanthine A1R radiotracers and highly potent CNS A1R drugs.Keywords
Funding Information
- Jess and Mildred Fisher College of Science and Mathematics
- National Institute of Diabetes and Digestive and Kidney Diseases (ZIADK031117)
- National Institute on Alcohol Abuse and Alcoholism (ZIA-AA000550)
This publication has 23 references indexed in Scilit:
- Explosion Hazards of Sodium Hydride in Dimethyl Sulfoxide, N,N-Dimethylformamide, and N,N-DimethylacetamideOrganic Process Research & Development, 2019
- Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic ActivityJournal of Medicinal Chemistry, 2019
- Imaging P‐Glycoprotein Function at the Blood–Brain Barrier as a Determinant of the Variability in Response to Central Nervous System DrugsClinical Pharmacology & Therapeutics, 2019
- Preclinical Evaluation of the First Adenosine A1 Receptor Partial Agonist Radioligand for Positron Emission Tomography ImagingJournal of Medicinal Chemistry, 2018
- Synthesis and Pharmacological Evaluation of Identified and Putative Metabolites of the A1Adenosine Receptor Antagonist 8‐Cyclopentyl‐3‐(3‐fluoropropyl)‐1‐propylxanthine (CPFPX)ChemMedChem, 2017
- Adenosine Receptor PET Imaging in Human Brain2014
- Adenosine Receptors and the Central Nervous System2009
- Metabolism of the A1 adenosine receptor PET ligand [18F]CPFPX by CYP1A2: implications for bolus/infusion PET studiesNuclear Medicine and Biology, 2006
- Synthesis and evaluation of [11C]FR194921 as a nonxanthine-type PET tracer for adenosine A1 receptors in the brainNuclear Medicine and Biology, 2005
- Evaluation of carbon-11 labeled KF15372 and its ethyl and methyl derivatives as a potential CNS adenosine A1 receptor ligandNuclear Medicine and Biology, 1997